Journal of ethnopharmacology
February 10, 2024
Alberto Hernandez-Leon, Raúl Iván Escamilla-Orozco, Aylín R Tabal-Robles et al.
29 citations
High doses of Psilocybe cubensis mushroom, given orally or by injection, produced antidepressant- and anxiety-reducing effects in mice without signs of neurotoxicity. The mushroom's polar aqueous extract, which contained psilocybin and psilocin, was particularly effective. In behavioral tests, the mushroom and its extracts matched the effects of standard antidepressant and anti-anxiety drugs. The lethal dose was greater than 2000 mg/kg, indicating low acute toxicity. These preclinical results suggest the mushroom may be a safe and effective treatment for anxiety and depression.
Ciencias Sociales y Religión
December 19, 2023
L. Serrano, Osiris Sinuhé González Romero, Leticia Romero-Bautista
1 citation
Over the past two decades, research has explored the therapeutic effects of psilocybin on the human body and mind. This article argues that science and spirituality are not mutually exclusive, critically examining conceptual frameworks such as psychedelics, hallucinogens, entheogens, and neurotropics, as well as the role of psychoactive compounds in evolution, specifically psilocybin-containing mushrooms. Based on a bibliographic analysis, it investigates the role of Psilocybe spp. mushrooms in human evolution and offers a critical analysis of their cultural uses.
Journal of the Mexican Chemical Society
July 7, 2026
Aylín R. Tabal-Robles, J. Martin Torres-Valencia, Leticia Romero-Bautista et al.
A review of chemical studies on Psilocybe mushrooms, covering publications from 1958 to 2025, identified at least 50 different metabolites across 32 species. Most metabolites were alkaloids with indole structures, responsible for psychotropic properties, but amino acids, terpenoids, and saccharides were also reported. The genus comprises about 165 hallucinogenic species, yet information on non-alkaloid metabolites remains scarce.
Molecules
April 18, 2026
Flor Eréndira Sánchez-cortés, Nelly Maritza Vega-Rivera, Raúl Iván Escamilla-Orozco et al.
Microdosing an aqueous extract of Psilocybe cubensis mushrooms produces anxiolytic and antidepressant-like effects in mice comparable to a single macrodose and the antidepressant fluoxetine. Over ten days of repeated microdosing, the extract also altered brain electrical activity (electrocorticography), promoted dendritic maturation in hippocampal neurons, and changed corticosterone levels. These findings suggest that P. cubensis may offer a therapeutic alternative for anxiety and depression, with microdosing providing benefits similar to larger doses.